Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Anouk E. J. Latenstein*, Lydia G. M. van der Geest, Bert A. Bonsing, Bas Groot Koerkamp, Nadia Haj Mohammad, Ignace H. J. T. de Hingh, Vincent E. de Meijer, Izaak Q. Molenaar, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Joanne Verheij, Pauline A. J. Vissers, Judith de Vos-Geelen, Olivier R. Busch, Casper H. J. van Eijck, Hanneke W. M. van Laarhoven, Marc G. Besselink, Johanna W. Wilmink, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Web of Science)

Abstract

Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.

Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.

Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trend

Conclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.

Original languageEnglish
Pages (from-to)83-93
Number of pages11
JournalEuropean Journal of Cancer
Volume125
DOIs
Publication statusPublished - Jan 2020

Keywords

  • BODY
  • CANCER SURGERY
  • CENTRALIZATION
  • CHEMOTHERAPY
  • Epidemiology
  • GEMCITABINE
  • IMPACT
  • Incidence
  • PANCREATICODUODENECTOMY
  • Pancreatic cancer
  • RESECTION
  • Survival
  • EPIDEMIOLOGY

Cite this